FOXR2

FOXR2 is a forkhead transcription factor that functions as a pan-cancer oncogene, transforming cells and driving proliferation across diverse lineages including CNS-embryonal tumors, neuroblastoma, and multiple carcinomas (PMID:24599127, PMID:27346356, PMID:35802025). Its central oncogenic mechanism is the potentiation of MYC-family transcription factors: FOXR2 forms a stable complex with MYC and MAX to enhance MYC transcriptional activity (PMID:27346356), and in neuroblastoma it binds and stabilizes MYCN protein, with FOXR2 loss reducing MYCN levels and triggering cell-cycle arrest and death (PMID:34110923). FOXR2 is aberrantly switched on in cancer through hypomethylation of a novel alternative promoter, and once expressed it co-opts ETS-family transcriptional circuits to sustain proliferation (PMID:35802025); chromatin-binding profiles confirm association with ETS networks and direct binding at transcription factors that initiate gliogenesis (PMID:39495206). Functionally it activates the MEK/ERK pathway by suppressing the endogenous RAS inhibitor DIRAS3, rendering FOXR2-expressing progenitors sensitive to MEK inhibition (PMID:39220247). In vivo, FOXR2 overexpression in a Trp53-deficient background or prenatal targeting to the ganglionic eminences generates CNS-embryonal/cortical tumors that recapitulate NB-FOXR2 molecular signatures, identifying medial ganglionic eminence progenitors as a cell of origin (PMID:30976792, PMID:39220247, PMID:39495206). FOXR2 protein abundance is constrained by PJA1-mediated ubiquitin-proteasomal degradation (PMID:33839405).

1. 2014 High

   Established FOXR2 as a bona fide oncogene and placed it functionally within SHH signaling, answering whether the gene actively drives transformation rather than being a passenger.

   Evidence Transposon insertional mutagenesis screen in mouse brain with NIH3T3 transformation, GNP proliferation, and Gli-luciferase reporter assays

   PMID:24599127

   Open questions at the time

   • Did not define direct DNA-binding targets of FOXR2
   • Cooperation with Gli1 shown by reporter, not by genomic occupancy
2. 2016 High

   Identified the core biochemical mechanism by showing FOXR2 forms a stable MYC/MAX complex to potentiate MYC activity, linking the oncogene to a defined transcriptional engine.

   Evidence Proteomic interaction network Co-IP/MS, functional proliferation assays, and FOXR2-knockdown xenografts

   PMID:27346356

   Open questions at the time

   • Stoichiometry and structural basis of the FOXR2-MYC-MAX complex not resolved
   • Genome-wide consequences on MYC target genes not mapped
3. 2016 Medium

   Extended FOXR2 oncogenicity to a carcinoma context and nominated β-catenin, Skp2, c-Myc, and Gli-1 as downstream effectors.

   Evidence RNAi knockdown, colony formation, xenograft, and qRT-PCR effector profiling in hepatocellular carcinoma cells

   PMID:26846213

   Open questions at the time

   • Downstream effectors inferred from expression, not direct binding
   • No biochemical pathway placement
4. 2017 Medium

   A series of carcinoma studies repeatedly linked FOXR2-driven proliferation and invasion to Wnt/β-catenin and Hedgehog pathway marker changes, suggesting recurrent pathway engagement across tissues.

   Evidence RNAi knockdown/overexpression with Western blot of pathway markers, cell-cycle, invasion/EMT assays, and xenografts in glioma, prostate, colorectal, and NSCLC cells

   PMID:28068638 PMID:28548041 PMID:28915588 PMID:29634928

   Open questions at the time

   • Pathway placement based on marker correlation, not direct transcriptional or biochemical reconstitution
   • Whether Wnt/Hedgehog effects are direct or secondary to MYC potentiation unresolved
5. 2017 Medium

   Defined post-transcriptional control of FOXR2 by demonstrating direct microRNA targeting, beginning to explain how FOXR2 levels are tuned.

   Evidence TargetScan prediction with luciferase 3'UTR reporter and Western blot of miR-202 in endometrial adenocarcinoma; later miR-152/HOTAIR axis by luciferase reporter in prostate cancer

   PMID:28827892 PMID:31269585

   Open questions at the time

   • Physiological relevance of these miRNA axes in vivo not established
   • Single-lab validation
6. 2019 High

   Provided in vivo proof that FOXR2 initiates CNS-embryonal tumors and that tumor cells possess tumor-initiating properties, moving beyond cell-line correlation.

   Evidence Transgenic Foxr2-overexpression/Trp53-knockout mouse with histology, sphere formation, transplantation, and gene expression profiling

   PMID:30976792

   Open questions at the time

   • Cell of origin not precisely defined in this model
   • Molecular driver mechanism within the tumors not dissected
7. 2021 High

   Showed FOXR2 stabilizes MYCN protein in neuroblastoma, providing a non-amplification route to MYCN dependence and a direct vulnerability.

   Evidence FOXR2-MYCN immunoprecipitation, knockdown with MYCN Western blot, cell-cycle/growth assays, transcriptomics, and patient tumor validation

   PMID:34110923

   Open questions at the time

   • Mechanism by which FOXR2 protects MYCN from degradation not defined
   • Whether MYCN and MYC/MAX engagement are mutually exclusive unknown
8. 2021 Medium

   Identified PJA1 as the E3 ligase controlling FOXR2 turnover, establishing how the oncoprotein's abundance is restrained.

   Evidence Co-expression, ubiquitination assay, and invasion/apoptosis assays in lung adenocarcinoma

   PMID:33839405

   Open questions at the time

   • Ubiquitination site and degron on FOXR2 not mapped
   • Single-lab finding without in vivo confirmation
9. 2022 High

   Explained how FOXR2 becomes aberrantly expressed in cancer—via hypomethylation of a novel alternative promoter—and that it co-opts ETS transcriptional circuits, unifying its pan-cancer activation mechanism.

   Evidence Pan-cancer DNA methylation analysis, functional promoter validation, knockdown proliferation readouts, and transcriptional circuit analysis across >10,000 samples

   PMID:35802025

   Open questions at the time

   • What triggers promoter hypomethylation in tumors is unknown
   • Direct ETS partner identity not resolved
10. 2024 High

    Placed FOXR2 mechanistically upstream of MEK/ERK by showing it suppresses the RAS inhibitor DIRAS3, and identified a druggable vulnerability.

    Evidence Human ESC-derived MGE progenitor model with FOXR2 overexpression, transcriptomics, MEK/ERK Western blot, trametinib treatment, and in vivo tumorigenicity

    PMID:39220247

    Open questions at the time

    • Whether DIRAS3 suppression is a direct transcriptional effect of FOXR2 not shown
    • Relationship of MEK/ERK activation to MYC potentiation unclear
11. 2025 High

    Mapped FOXR2 chromatin occupancy and demonstrated that prenatal targeting to ganglionic eminences generates tumors recapitulating NB-FOXR2 signatures, anchoring cell of origin and direct genomic targets.

    Evidence FOXR2 chromatin binding profiling, in vivo prenatal Foxr2 targeting, and single-cell transcriptomics integrated with a normal brain reference atlas in mice

    PMID:39495206

    Open questions at the time

    • Direct FOXR2 consensus binding motif not fully defined
    • How ETS-network co-option translates to gliogenic initiation mechanistically unresolved

• How FOXR2's distinct partner engagements (MYC/MAX, MYCN stabilization, ETS circuits, DIRAS3/MEK-ERK) are integrated into a single coherent transcriptional program, and the structural basis of these interactions, remains unresolved.
• No structural model of FOXR2 or its complexes
• No unified genome-wide map reconciling MYC, ETS, and Wnt/Hedgehog outputs
• Direct vs indirect nature of several pathway effects unresolved